The DOI matches its Crossref record; 436 of the 436 references it cites were found in a registry or an index.
Small Molecule Kinase Inhibitor Drugs (1995–2021): Medical Indication, Pharmacology, and Synthesis
Open accessAbstract
The central role of dysregulated kinase activity in the etiology of progressive disorders, including cancer, has fostered incremental efforts on drug discovery programs over the past 40 years. As a result, kinase inhibitors are today one of the most important classes of drugs. The FDA approved 73 small molecule kinase inhibitor drugs until September 2021, and additional inhibitors were approved by other regulatory agencies during that time. To complement the published literature on clinical kinase inhibitors, we have prepared a review that recaps this large data set into an accessible format for the medicinal chemistry community. Along with the therapeutic and pharmacological properties of each kinase inhibitor approved across the world until 2020, we provide the synthesis routes originally used during the discovery phase, many of which were only available in patent applications. In the last section, we also provide an update on kinase inhibitor drugs approved in 2021.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–436 of 436
Robarge, K. D., Lee, W., Eigenbrot, C. W., Ultsch, M. H., Wiesmann, C., Heald, R. A., Price, S., Hewitt, J. F. M., Jackson, P. S., Savy, P., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.08.008 · Cited by 44
The effects of an intracellular calcium antagonist HA 1077 on delayed cerebral vasospasm in dogs
Shibuya, M., Suzuki, Y., Takayasu, M., et al. (1988) · Acta Neurochirurgica · doi:10.1007/bf01541267 · Cited by 43
Abstract LB-100: Discovery of HM61713 as an orally available and mutant EGFR selective inhibitor
Lee, K., Cha, M. Y., Kim, M., Song, J. Y., Lee, J., Kim, Y. H., Lee, Y.-M., Suh, K. H., & Son, J. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-lb-100 · Cited by 43
Conchon, M., Freitas, C. M. B. D. M., Rego, M. A. D. C., & Braga, J. W. R. (2010) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.5581/1516-8484.20110034 · Cited by 42
Larotrectinib for the treatment of TRK fusion solid tumors
Laetsch, T. W., & Hawkins, D. S. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1538796 · Cited by 42
Alexeeva, M., Åberg, E., Engh, R. A., & Rothweiler, U. (2015) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s1399004715005106 · Cited by 41
Patent Review of Manufacturing Routes to Oncology Drugs: Carfilzomib, Osimertinib, and Venetoclax
Hughes, D. L. (2016) · Organic Process Research & Development · doi:10.1021/acs.oprd.6b00374 · Cited by 41
Targeting the epidermal growth factor receptor in solid tumors: focus on safety
Lucchini, E., Pilotto, S., Spada, E. L., Melisi, D., Bria, E., & Tortora, G. (2014) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2014.904283 · Cited by 40
Dayal, N., Mikek, C. G., Hernandez, D. E., Naclerio, G. A., Chu, E. F. Y., Carter‐Cooper, B., Lapidus, R. G., & Sintim, H. O. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.06.089 · Cited by 40
Carbohydrate Kinases: A Conserved Mechanism Across Differing Folds
Roy, S., Vivoli, M., & Harmer, N. J. (2019) · Catalysts · doi:10.3390/catal9010029 · Cited by 39
Roskoski, R. J. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104725 · Cited by 38
Wu, X., Wang, L., Han, Y., Regan, N., Li, P.-K., Villalona, M. A., Hu, X., Briesewitz, R., & Pei, D. (2011) · ACS Combinatorial Science · doi:10.1021/co200057n · Cited by 36
Abstract 2515: Preclinical Development of ARRY-162, A Potent and Selective MEK 1/2 Inhibitor
Lee, P. A., Wallace, E. M., Marlow, A., Yeh, T. C., Marsh, V., Anderson, D. A., Woessner, R. D., Hurley, B., Lyssikatos, J. P., Poch, G., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-2515 · Cited by 36
Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update
Eşkazan, A. E., & Keskin, D. (2017) · Therapeutic Advances in Hematology · doi:10.1177/2040620717719851 · Cited by 36
Early treatment-related neutropenia predicts response to palbociclib
McAndrew, N. P., Dickson, M. A., Clark, A. S., Troxel, A. B., O’Hara, M. H., Colameco, C., Gallager, M., Gramlich, K., Zafman, K. B., Vaughn, D. J., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0967-7 · Cited by 36
Kozaki, R., Vogler, M., Walter, H. S., Jayne, S., Dinsdale, D., Siebert, R., Dyer, M. J. S., & Yoshizawa, T. (2018) · Cancers · doi:10.3390/cancers10040127 · Cited by 33
Qian, J., Yan, P., Che, D., Zhou, Q., & Li, Y. (2014) · Tetrahedron Letters · doi:10.1016/j.tetlet.2014.01.053 · Cited by 33
Keating, G. M. (2016) · Drugs · doi:10.1007/s40265-016-0562-7 · Cited by 28
Liu, Y., Zhang, Y., Feng, G., Niu, Q., Xu, S., Yan, Y., Li, S., & Jing, M. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.5094 · Cited by 28
Jabbour, E. J., & Lipton, J. H. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.05.012 · Cited by 27
Liu, D., Jiang, J., Zhang, L., Tan, F., Wang, Y., & Hu, P. (2011) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.5061 · Cited by 26
Cabozantinib for the treatment of renal cell carcinoma
Escudier, B. J., Lougheed, J. C., & Albiges, L. K. (2016) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2016.1258059 · Cited by 26
Nakajima, Y., Tojo, T., Morita, M., Hatanaka, K., Shirakami, S., Tanaka, A., Sasaki, H., Nakai, K., Mukoyoshi, K., Hamaguchi, H., et al. (2015) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c15-00036 · Cited by 25
Kim, Y., Apetri, M. M., Luo, B.-B., Settleman, J., & Anderson, K. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0326 · Cited by 25
Gokhale, S., Lu, W., Zhu, S., Liu, Y., Hart, R. P., Rabinowitz, J. D., & Xie, P. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900658 · Cited by 24
Sanford, D., Kantarjian, H., Skinner, J. A., Jabbour, E. J., & Cortes, J. E. (2015) · Haematologica · doi:10.3324/haematol.2015.132845 · Cited by 23
Brandhuber, B. J., Haas, J., Tuch, B. B., Ebata, K. T., Bouhana, K., McFaddin, E., Williams, L., Winski, S. L., Brown, E., Burkhard, M., et al. (2016) · European Journal of Cancer · doi:10.1016/s0959-8049(16)33028-3 · Cited by 23
Synthesis and biological evaluation of rapamycin-derived, next generation small molecules
Guduru, S. K. R., & Arya, P. (2017) · MedChemComm · doi:10.1039/c7md00474e · Cited by 22
Pheneger, T., Bouhana, K., Anderson, D., Garrus, J. E., Ahrendt, K. A., Allen, S. J., von Carlowitz, I., Greschuk, J., Gross, S. D., Hoffman, K. L., et al. (2009) · Cancer Research · Cited by 21
Almonertinib-induced interstitial lung disease
Jiang, T., Luo, Y., & Wang, B. (2021) · Medicine · doi:10.1097/md.0000000000024393 · Cited by 19
An alternative synthesis of the non-small cell lung carcinoma drug afatinib
Kovačević, T., Mesić, M., Avdagić, A., & Žegarac, M. (2018) · Tetrahedron Letters · doi:10.1016/j.tetlet.2018.10.026 · Cited by 16
Molica, S., Gianfelici, V., & Levato, L. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1724282 · Cited by 14
Lü, S., Camidge, D. R., Yang, C., Zhou, J., Guo, R., Chiu, C., Chang, G., Shiah, H.-S., Chen, Y., Wang, C., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.618 · Cited by 10
Brigatinib: New-generation ALK inhibitor for nonsmall cell lung cancer
Umbela, S., Ghacha, S., Matuknauth, R., Gause, S., Joshee, S., & Deshmukh, R. R. (2019) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2019.03.005 · Cited by 8
Oncogen Pharma Sdn Bhd, N. 3., Kumar, P., Dhande, P., Oncogen Pharma Sdn Bhd, N. 3., Mazlee, M. T. F., & Oncogen Pharma Sdn Bhd, N. 3. (2019) · Chemical Reports · doi:10.25082/cr.2019.01.001 · Cited by 7
(2002) · PubMed
Cited by
Properties of FDA-approved small molecule protein kinase inhibitors: A 2024 update
Roskoski, R. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107059 · Cited by 383
A Comprehensive Overview of Globally Approved JAK Inhibitors
Shawky, A. M., Almalki, F. A., Abdalla, A. N., Abdelazeem, A. H., & Gouda, A. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14051001 · Cited by 349
A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-024-02143-0 · Cited by 348
“As using ATP competitors is a well-established strategy for targeting kinases 57 , we selected the ATP-binding site as a pocket for compound generation.”
Properties of FDA-approved small molecule protein kinase inhibitors: A 2023 update
Roskoski, R. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2022.106552 · Cited by 273
Harnessing systematic protein–ligand interaction fingerprints for drug discovery
Zhao, Z., & Bourne, P. E. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.07.004 · Cited by 41
Metadata
- Authors
- Ayala-Aguilera, C. C., Valero, T., Lorente-Macías, Á., Baillache, D. J., Croke, S., & Unciti-Broceta, A.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2021-10-08
- Volume
- 65
- Issue
- 2
- Pages
- 1047-1131
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W3203420675
- Cited by
- 265
- References
- 436
- FWCI
- 12.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.